fasudil has been researched along with Brain Hemorrhage, Cerebral in 6 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In fasudil-treated rats, the internal carotid artery narrowing was ameliorated and L-NAME-induced regional constriction was abolished." | 1.43 | Vessel Dilation Attenuates Endothelial Dysfunction Following Middle Cerebral Artery Occlusion in Hyperglycemic Rats. ( Jiang, Z; Lin, XJ; Mu, ZH; Wang, LP; Wang, YT; Xi, Y; Yang, GY; Zhang, ZJ, 2016) |
| "Fasudil-treated Ccm1(+/-)Msh2(-/-) mice had a significantly decreased prevalence of CCM lesions compared with placebo controls." | 1.38 | Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease. ( Awad, IA; Ginsberg, MH; Liu, F; Marchuk, DA; McDonald, DA; Shenkar, R; Shi, C; Stockton, RA, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, J | 1 |
| Yao, GE | 1 |
| Zhou, HD | 1 |
| Jiang, XJ | 1 |
| Xie, P | 1 |
| Lee, HS | 1 |
| Kim, KS | 1 |
| Lim, HS | 1 |
| Choi, M | 1 |
| Kim, HK | 1 |
| Ahn, HY | 1 |
| Shin, JC | 1 |
| Joe, YA | 1 |
| Mu, ZH | 1 |
| Jiang, Z | 1 |
| Lin, XJ | 1 |
| Wang, LP | 1 |
| Xi, Y | 1 |
| Zhang, ZJ | 1 |
| Wang, YT | 1 |
| Yang, GY | 1 |
| McDonald, DA | 1 |
| Shi, C | 1 |
| Shenkar, R | 1 |
| Stockton, RA | 1 |
| Liu, F | 1 |
| Ginsberg, MH | 1 |
| Marchuk, DA | 1 |
| Awad, IA | 1 |
| Ishiguro, M | 1 |
| Kawasaki, K | 1 |
| Suzuki, Y | 2 |
| Ishizuka, F | 1 |
| Mishiro, K | 1 |
| Egashira, Y | 1 |
| Ikegaki, I | 2 |
| Tsuruma, K | 1 |
| Shimazawa, M | 1 |
| Yoshimura, S | 1 |
| Iwama, T | 1 |
| Hara, H | 1 |
| Toshima, Y | 1 |
| Satoh, S | 1 |
| Asano, T | 1 |
| Shibuya, M | 1 |
6 other studies available for fasudil and Brain Hemorrhage, Cerebral
| Article | Year |
|---|---|
Clinical investigation of fasudil for the prevention of cerebral vasospasm in extracranial carotid artery stenting.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Calcium Channel Blockers; Carotid Arteries; Cer | 2014 |
Priming Wharton's jelly-derived mesenchymal stromal/stem cells with ROCK inhibitor improves recovery in an intracerebral hemorrhage model.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blotting, Western; Cell Differentiation; Cel | 2015 |
Vessel Dilation Attenuates Endothelial Dysfunction Following Middle Cerebral Artery Occlusion in Hyperglycemic Rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain; Cerebral Angiography; Cerebral Arteri | 2016 |
Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain; Cerebral Hemorrhage; Enzyme Inhibitor | 2012 |
A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9-related hemorrhagic transformation in mice treated with tissue plasminogen activator.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blotting, Western; Cells, Cultured; Cerebral | 2012 |
Thromboxane A2 synthetase inhibitor failed to ameliorate the arterial narrowing during the chronic phase of cerebral vasospasm.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cerebral Hemorrhage; Dogs; Enzyme Inhibitors | 1997 |